Results 131 to 140 of about 20,430,225 (174)
Some of the next articles are maybe not open access.
Non-clear cell advanced kidney cancer
Anti-Cancer Drugs, 2011Renal cell carcinoma (RCC) accounts for approximately 3% of all new cancer diagnosis every year. RCC arises from the renal epithelium and represents 85% of all kidney tumors. According to histology, these neoplasms are divided into the following types: clear cell, papillary, chromophobe, oncocytoma, collecting duct, and unclassified. Approximately, 75%
Pedro, Sánchez +2 more
openaire +2 more sources
[Non-clear cell renal cell carcinoma].
Urologie (Heidelberg, Germany)Non-clear cell renal cell carcinomas (nccRCC) account for approximately 20-25% of renal cell carcinomas. Approximately 20 different histologically and/or molecularly defined entities are subsumed under nccRCC. Many entities only have a share of 1% or less.
Marit, Ahrens, Lothar, Bergmann
openaire +3 more sources
Therapy for Non-Clear Cell Histologies in Renal Cancer
Current Clinical Pharmacology, 2011The advent of targeted systemic therapies has significantly improved treatment options for patients with metastatic renal cell carcinoma (RCC). Multiple agents that inhibit angiogenesis cell growth and proliferation via the VEGF and mTOR (TORC1) pathways have been USFDA-approved for locally advanced or metastatic renal cell carcinoma in recent years ...
Rhonda L, Bitting +2 more
openaire +2 more sources
Non-Clear Cell Renal Cell Carcinoma - Pathology and Treatment Options
Oncology Research and Treatment, 2019Non-clear cell renal cell carcinomas (nccRCC) are rare diseases with heterogeneous histopathologically and genetically defined entities. The clinical data on optimal systemic treatments of nccRCC is rather limited. In this review, the current World Health Organization (WHO) classification of nccRCC based on histopathologic and genetic findings is ...
Marit, Ahrens +3 more
openaire +2 more sources
Comparing Everolimus to Sunitinib in Non–clear-cell Renal Cell Carcinoma
European Urology, 2016Compared to its more common clear-cell counterpart, metastatic non–clear-cell renal cell carcinoma (non-ccRCC) is less responsive to vascular endothelial growth factor (VEGF)-targeted therapy or inhibitors of the mammalian target of rapamycin (mTOR) [1]. It is unknown if VEGF targeting is superior to mTOR inhibition.
Axel, Bex, Börje, Ljungberg
openaire +2 more sources
Pathology and systemic therapy of non-clear cell renal cell carcinoma: an overview
Expert Review of Anticancer Therapy, 2021Introduction: Non-clear cell renal cell carcinoma (nccRCC) represents a highly heterogenous group of kidney cancer entities. As most clinical trials predominantly include patients with clear cell RCC (ccRCC), nccRCC treatment guidelines are mainly extrapolated from recommendations in ccRCC.
Lothar, Bergmann +3 more
openaire +2 more sources
Advanced Non–Clear Cell Kidney Cancer
The Cancer Journal, 2020AbstractNon–clear cell renal cell carcinoma (nccRCC) accounts for approximately 25% of RCC diagnoses. Although broadly labeled as “nccRCC,” they comprised a host of histologies that include papillary, chromophobe, unclassified, and others. Moreover, these histological variants are further subclassified on the basis of genomic profiling, thereby ...
Moshe C, Ornstein, Thomas E, Hutson
openaire +2 more sources
Management of Non-clear Cell Renal Cell Carcinoma
2013Renal cell carcinoma comprises a large, heterogeneous group of tumors. Although clear cell renal cancer is the most common subtype, 20–25 % of renal malignancies are of variant histology. Papillary renal cell carcinoma represents the most common non-clear cell histology, with unclassified, chromophobe, collecting duct, and renal medullary carcinoma ...
Henry J. Conter +2 more
openaire +1 more source
Management of non–clear cell renal cell carcinoma: Current approaches
Urologic Oncology: Seminars and Original Investigations, 2017Non-clear cell renal cell carcinoma includes several histological variants. Tumor biology has significant effect on the duration of the disease. Prognosis at formally similar disease stages may differ despite same surgical treatment approaches to clear and non-clear cell renal cell carcinomas.
openaire +2 more sources
An update on the treatment paradigm for non-clear cell renal cell carcinoma
Expert Review of Clinical PharmacologyNon - clear cell renal cell carcinoma (nccRCC) encompasses a heterogeneous group of rare malignancies, representing approximately 20-25% of all renal cancers. Unlike clear cell RCC (ccRCC), these subtypes - papillary, chromophobe, collecting duct, translocation, molecularly defined variants and others - display distinct biological behaviors, genetic ...
Alessandro Rametta +9 more
openaire +2 more sources